Publication: Quinolone Resistance Determinants of Clinical Salmonella Enteritidis in Thailand
Issued Date
2017-10-01
Resource Type
ISSN
19318448
10766294
10766294
Other identifier(s)
2-s2.0-85031288388
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Microbial Drug Resistance. Vol.23, No.7 (2017), 885-894
Suggested Citation
Fuangfa Utrarachkij, Chie Nakajima, Ruchirada Changkwanyeun, Kanokrat Siripanichgon, Siriporn Kongsoi, Srirat Pornruangwong, Kanjana Changkaew, Risa Tsunoda, Yutaka Tamura, Orasa Suthienkul, Yasuhiko Suzuki Quinolone Resistance Determinants of Clinical Salmonella Enteritidis in Thailand. Microbial Drug Resistance. Vol.23, No.7 (2017), 885-894. doi:10.1089/mdr.2015.0234 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/42749
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Quinolone Resistance Determinants of Clinical Salmonella Enteritidis in Thailand
Abstract
© Copyright 2017, Mary Ann Liebert, Inc. 2017. Salmonella Enteritidis has emerged as a global concern regarding quinolone resistance and invasive potential. Although quinolone-resistant S. Enteritidis has been observed with high frequency in Thailand, information on the mechanism of resistance acquisition is limited. To elucidate the mechanism, a total of 158 clinical isolates of nalidixic acid (NAL)-resistant S. Enteritidis were collected throughout Thailand, and the quinolone resistance determinants were investigated in the context of resistance levels to NAL, norfloxacin (NOR), and ciprofloxacin (CIP). The analysis of point mutations in type II topoisomerase genes and the detection of plasmid-mediated quinolone resistance genes showed that all but two harbored a gyrA mutation, the qnrS1 gene, or both. The most commonly affected codon in mutant gyrA was 87, followed by 83. Double codon mutation in gyrA was found in an isolate with high-level resistance to NAL, NOR, and CIP. A new mutation causing serine to isoleucine substitution at codon 83 was identified in eight isolates. In addition to eighteen qnrS1-carrying isolates showing nontypical quinolone resistance, one carrying both the qnrS1 gene and a gyrA mutation also showed a high level of resistance. Genotyping by multilocus variable number of tandem repeat analysis suggested a possible clonal expansion of NAL-resistant strains nationwide. Our data suggested that NAL-resistant isolates with single quinolone resistance determinant may potentially become fluoroquinolone resistant by acquiring secondary determinants. Restricted therapeutic and farming usage of quinolones is strongly recommended to prevent the emergence of fluoroquinolone-resistant isolates.